Keros Therapeutics, Inc. Summary

Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for hematological and musculoskeletal disorders. Their lead product candidate, KER-050, targets low blood cell counts in patients with myelodysplastic syndromes and myelofibrosis. They are also developing KER-047, a small molecule product candidate for anemia and fibrodysplasia ossificans progressiva, and KER-012 for bone loss disorders and pulmonary arterial hypertension. Founded in 2015, the company is based in Lexington, Massachusetts.
Symbol
KROS
General Information
Company Name
Keros Therapeutics, Inc.
Sector
Healthcare
Industry
Biotechnology
Stock Multiplier
0.57X
P/E Ratio
0.7X
Assets
Cash and Cash Equivalents
720.54 Million change
Total Current Assets
759.51 Million change
Total Non-current Assets
25.05 Million change
Net Accounts Receivable
17.29 Million change
Property, Plant, and Equipment
N/A change
Total Assets
784.56 Million change
Net Property, Plant, and Equipment
4.47 Million change
Liabilities
Total Liabilities
55.69 Million change
Total Current Liabilities
39.38 Million change
Total Non-current Liabilities
16.31 Million change
Accounts Payable
6.64 Million
Share Information
Shares Issued
40.56 Million change
Basic Shares Outstanding
40.56 Million change
Shares Authorized
200 Million
Shareholders' Equity
Retained Earnings
-420.33 Million change
Total Shareholders' Equity
728.87 Million change
Income
Gross Revenue
211.19 Million change
Net Income
148.45 Million change
Basic Earnings per Share
3.66 change
Diluted Earnings per Share
3.62 change
Operating Income
152.04 Million change
Expenses
Research and Development
48.71 Million change
Operating Expenses
59.21 Million change

Stock Info

Current Price
$14.51
Market Cap
$588.56M
Monthly Low
$13.34
Yearly Low
$9.55
Monthly High
$14.57
Yearly High
$700
Monthly Avg
$14.04
Yearly Avg
$29.49
Monthly Volatility
Low
Yearly Volatility
High

Recent Keros Therapeutics, Inc. News

07/06/2025
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Moderate Buy" from Brokerages
06/11/2025
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Moderate Buy" from Analysts
06/10/2025
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
06/06/2025
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
05/30/2025
Keros Therapeutics (NASDAQ:KROS) Trading Down 3.9% - Here's What Happened
05/29/2025
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
05/29/2025
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
05/20/2025
Tema Etfs LLC Purchases Shares of 35,663 Keros Therapeutics, Inc. (NASDAQ:KROS)
05/15/2025
Occudo Quantitative Strategies LP Invests $1.64 Million in Keros Therapeutics, Inc. (NASDAQ:KROS)
05/10/2025
What is Leerink Partnrs' Estimate for KROS FY2025 Earnings?

Keros Therapeutics, Inc. Stock vs Fundamentals

$20$40$60$80$100M$200M$300M$400M$500M$600M$700MStock PriceTotal Shareholders' EquityOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJuly−1.0−0.50.00.51.0BUYSELLFinancial Signal Strength
AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJuly$10$20$30$40$50$60$70$80$90$-100M$0$100M$200M$300M$400M$500M$600M$700M$800MStock PriceTotal Shareholders' EquityStock Price vs Total Shareholders' Equity

Recommendation

Hold

Keros Therapeutics, Inc. Stock Forecast

category
sentiment
volatility
growth
forecast
KROS
+2%
Cohorts
+1.3%
Industry
+2.2%
Biotechnology
Industry Forecast
AugustSeptemberOctober-2%0%1%2%3%4%5%6%7%8%10%12%14%16%18%Industry Forecast
Data as of: 07/27/2025
Outperformers
America Great Health
+15%
FibroGen, Inc.
+15%
Replimune Group, Inc.
+13%
Underperformers
Nuvation Bio Inc.
-4%
Atara Biotherapeutics, Inc.
-2%
Aurinia Pharmaceuticals Inc.
-2%

KROS Cohorts

Genetic Technology
+29%
+15%
+21%
+16%
+2%
+29%
+14%
-5%
+2%
+18%